Figures & data
Figure 1 Study flow diagram.
![Figure 1 Study flow diagram.](/cms/asset/b30e0cb5-cc8d-4b9d-9629-24df507a47ff/dcop_a_130140_f0001_b.jpg)
Table 1 Epidemiological characteristics according to subtypes of subjects with mild-to-moderate airflow limitation identified by k-means clustering for k=5 clusters
Figure 2 Distribution of five clusters according to mean FEV1% predicted and amount of smoking.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
![Figure 2 Distribution of five clusters according to mean FEV1% predicted and amount of smoking.](/cms/asset/44e5a041-a7ad-479d-9a27-a6a096804310/dcop_a_130140_f0002_b.jpg)
Table 2 Lung function and socioeconomic characteristics according to subtypes of subjects with mild-to-moderate airflow limitation identified by k-means clustering for k=5 clusters
Table 3 Respiratory medication prescribed according to subtypes of subjects with mild-to-moderate airflow limitation
Figure 3 Prescription patterns of respiratory medication.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; IVCS, intravenous corticosteroids; LABA, long-acting beta-2 agonists; LAMA, long-acting muscarinic antagonists; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroids; SAMA, short-acting muscarinic antagonists; SABA, short-acting beta-2 agonists.
![Figure 3 Prescription patterns of respiratory medication.](/cms/asset/2a68f585-b0c6-406e-a6d5-fc103d6b1f42/dcop_a_130140_f0003_b.jpg)
Table 4 Comorbidities according to subtypes of subjects with mild-to-moderate airflow limitation
Table 5 Insurance-related data according to subtypes of subjects with mild-to-moderate airflow limitation
Table 6 Health care utilization according to subtypes of subjects with mild-to-moderate airflow limitation